Arkolith/Insider Trading/ATHA/Form 4/A

Litton Mark James

President and CEO, DirectorAthira Pharma, Inc. (ATHA) · full profile →Form 4/A · filed Oct 3, 2024
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
1
0 non-derivative · 1 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Oct 3, 2024Grant(A)325K—$0325K

Transaction Codes

A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4/A filing (accession 0001415889-24-024712) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4/A XML